TDP-43 is a key player in the clinical features associated with Alzheimer’s disease
The aim of this study was to determine whether the TAR DNA-binding protein of 43 kDa (TDP-43) has any independent effect on the clinical and neuroimaging features typically ascribed to Alzheimer’s disease (AD) pathology, and whether TDP-43 pathology could help shed light on the phenomenon of resilie...
Saved in:
| Published in | Acta neuropathologica Vol. 127; no. 6; pp. 811 - 824 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.06.2014
Springer Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0001-6322 1432-0533 1432-0533 |
| DOI | 10.1007/s00401-014-1269-z |
Cover
Loading…
| Abstract | The aim of this study was to determine whether the TAR DNA-binding protein of 43 kDa (TDP-43) has any independent effect on the clinical and neuroimaging features typically ascribed to Alzheimer’s disease (AD) pathology, and whether TDP-43 pathology could help shed light on the phenomenon of resilient cognition in AD. Three-hundred and forty-two subjects pathologically diagnosed with AD were screened for the presence, burden and distribution of TDP-43. All had been classified as cognitively impaired or normal, prior to death. Atlas-based parcellation and voxel-based morphometry were used to assess regional atrophy on MRI. Regression models controlling for age at death, apolipoprotein
ε
4 and other AD-related pathologies were utilized to explore associations between TDP-43 and cognition or brain atrophy, stratified by Braak stage. In addition, we determined whether the effects of TDP-43 were mediated by hippocampal sclerosis. One-hundred and ninety-five (57 %) cases were TDP-positive. After accounting for age, apolipoprotein
ε
4 and other pathologies, TDP-43 had a strong effect on cognition, memory loss and medial temporal atrophy in AD. These effects were not mediated by hippocampal sclerosis. TDP-positive subjects were 10× more likely to be cognitively impaired at death compared to TDP-negative subjects. Greater cognitive impairment and medial temporal atrophy were associated with greater TDP-43 burden and more extensive TDP-43 distribution. TDP-43 is an important factor in the manifestation of the clinico-imaging features of AD. TDP-43 also appears to be able to overpower what has been termed resilient brain aging. TDP-43 therefore should be considered a potential therapeutic target for the treatment of AD. |
|---|---|
| AbstractList | The aim of this study was to determine whether the Tar DNA-binding protein of 43 kDa (TDP-43) has any independent effect on the clinical and neuroimaging features typically ascribed to Alzheimer's disease (AD) pathology, and whether TDP-43 pathology could help shed light on the phenomenon of resilient cognition in AD. Three-hundred and forty-two subjects pathologically diagnosed with AD were screened for the presence, burden and distribution of TDP-43. All had been classified as cognitively impaired or normal, prior to death. Atlas-based parcellation and voxel-based morphometry were used to assess regional atrophy on MRI. Regression models controlling for age at death, apolipoprotein ζ4 and other AD-related pathologies were utilized to explore associations between TDP-43 and cognition or brain atrophy, stratified by Braak stage. In addition, we determined whether the effects of TDP-43 were mediated by hippocampal sclerosis. One-hundred and ninety-five (57 %) cases were TDPpositive. After accounting for age, apolipoprotein ζ4 and other pathologies, TDP-43 had a strong effect on cognition, memory loss and medial temporal atrophy in AD. These effects were not mediated by hippocampal sclerosis. TDP-positive subjects were 10x more likely to be cognitively impaired at death compared to TDP-negative subjects. Greater cognitive impairment and medial temporal atrophy were associated with greater TDP-43 burden and more extensive TDP-43 distribution. TDP-43 is an important factor in the manifestation of the clinico-imaging features of AD. TDP-43 also appears to be able to overpower what has been termed resilient brain aging. TDP-43 therefore should be considered a potential therapeutic target for the treatment of AD. Keywords TDP-43 * Alzheimer disease * Resilience * APOE ζ4 * Braak stage * MRI The aim of this study was to determine whether the Tar DNA-binding protein of 43 kDa (TDP-43) has any independent effect on the clinical and neuroimaging features typically ascribed to Alzheimer's disease (AD) pathology, and whether TDP-43 pathology could help shed light on the phenomenon of resilient cognition in AD. Three-hundred and forty-two subjects pathologically diagnosed with AD were screened for the presence, burden and distribution of TDP-43. All had been classified as cognitively impaired or normal, prior to death. Atlas-based parcellation and voxel-based morphometry were used to assess regional atrophy on MRI. Regression models controlling for age at death, apolipoprotein ζ4 and other AD-related pathologies were utilized to explore associations between TDP-43 and cognition or brain atrophy, stratified by Braak stage. In addition, we determined whether the effects of TDP-43 were mediated by hippocampal sclerosis. One-hundred and ninety-five (57 %) cases were TDPpositive. After accounting for age, apolipoprotein ζ4 and other pathologies, TDP-43 had a strong effect on cognition, memory loss and medial temporal atrophy in AD. These effects were not mediated by hippocampal sclerosis. TDP-positive subjects were 10x more likely to be cognitively impaired at death compared to TDP-negative subjects. Greater cognitive impairment and medial temporal atrophy were associated with greater TDP-43 burden and more extensive TDP-43 distribution. TDP-43 is an important factor in the manifestation of the clinico-imaging features of AD. TDP-43 also appears to be able to overpower what has been termed resilient brain aging. TDP-43 therefore should be considered a potential therapeutic target for the treatment of AD. The aim of this study was to determine whether the TAR DNA-binding protein of 43kDa (TDP-43) independently has any effect on the clinical and neuroimaging features typically ascribed to Alzheimer’s disease (AD) pathology, and whether TDP-43 pathology could help shed light on the phenomenon of resilient cognition in AD. Three-hundred forty-two subjects pathologically diagnosed with AD were screened for the presence, burden and distribution of TDP-43. All had been classified as cognitively impaired or normal, prior to death. Atlas-based parcellation and voxel-based morphometry were used to assess regional atrophy on MRI. Regression models controlling for age at death, apolipoprotein ε4 and other AD-related pathologies were utilized to explore associations between TDP-43 and cognition or brain atrophy, stratified by Braak stage. Additionally, we determined whether the effects of TDP-43 were mediated by hippocampal sclerosis. One-hundred ninety-five (57%) cases were TDP-positive. After accounting for age, apolipoprotein ε4, and other pathologies, TDP-43 had a strong effect on cognition, memory loss, and medial temporal atrophy in AD. These effects were not mediated by hippocampal sclerosis. TDP-positive subjects were 10× more likely to be cognitively impaired at death compared to TDP-negative subjects. Greater cognitive impairment and medial temporal atrophy were associated with greater TDP-43 burden and more extensive TDP-43 distribution. TDP-43 is an important factor in the manifestation of the clinico-imaging features of AD. TDP-43 also appears to be able to overpower what has been termed resilient brain aging. TDP-43 therefore should be considered a potential therapeutic target for the treatment of AD. The aim of this study was to determine whether the TAR DNA-binding protein of 43 kDa (TDP-43) has any independent effect on the clinical and neuroimaging features typically ascribed to Alzheimer's disease (AD) pathology, and whether TDP-43 pathology could help shed light on the phenomenon of resilient cognition in AD. Three-hundred and forty-two subjects pathologically diagnosed with AD were screened for the presence, burden and distribution of TDP-43. All had been classified as cognitively impaired or normal, prior to death. Atlas-based parcellation and voxel-based morphometry were used to assess regional atrophy on MRI. Regression models controlling for age at death, apolipoprotein [straight epsilon]4 and other AD-related pathologies were utilized to explore associations between TDP-43 and cognition or brain atrophy, stratified by Braak stage. In addition, we determined whether the effects of TDP-43 were mediated by hippocampal sclerosis. One-hundred and ninety-five (57 %) cases were TDP-positive. After accounting for age, apolipoprotein [straight epsilon]4 and other pathologies, TDP-43 had a strong effect on cognition, memory loss and medial temporal atrophy in AD. These effects were not mediated by hippocampal sclerosis. TDP-positive subjects were 10× more likely to be cognitively impaired at death compared to TDP-negative subjects. Greater cognitive impairment and medial temporal atrophy were associated with greater TDP-43 burden and more extensive TDP-43 distribution. TDP-43 is an important factor in the manifestation of the clinico-imaging features of AD. TDP-43 also appears to be able to overpower what has been termed resilient brain aging. TDP-43 therefore should be considered a potential therapeutic target for the treatment of AD.[PUBLICATION ABSTRACT] The aim of this study was to determine whether the TAR DNA-binding protein of 43 kDa (TDP-43) has any independent effect on the clinical and neuroimaging features typically ascribed to Alzheimer’s disease (AD) pathology, and whether TDP-43 pathology could help shed light on the phenomenon of resilient cognition in AD. Three-hundred and forty-two subjects pathologically diagnosed with AD were screened for the presence, burden and distribution of TDP-43. All had been classified as cognitively impaired or normal, prior to death. Atlas-based parcellation and voxel-based morphometry were used to assess regional atrophy on MRI. Regression models controlling for age at death, apolipoprotein ε 4 and other AD-related pathologies were utilized to explore associations between TDP-43 and cognition or brain atrophy, stratified by Braak stage. In addition, we determined whether the effects of TDP-43 were mediated by hippocampal sclerosis. One-hundred and ninety-five (57 %) cases were TDP-positive. After accounting for age, apolipoprotein ε 4 and other pathologies, TDP-43 had a strong effect on cognition, memory loss and medial temporal atrophy in AD. These effects were not mediated by hippocampal sclerosis. TDP-positive subjects were 10× more likely to be cognitively impaired at death compared to TDP-negative subjects. Greater cognitive impairment and medial temporal atrophy were associated with greater TDP-43 burden and more extensive TDP-43 distribution. TDP-43 is an important factor in the manifestation of the clinico-imaging features of AD. TDP-43 also appears to be able to overpower what has been termed resilient brain aging. TDP-43 therefore should be considered a potential therapeutic target for the treatment of AD. The aim of this study was to determine whether the TAR DNA-binding protein of 43 kDa (TDP-43) has any independent effect on the clinical and neuroimaging features typically ascribed to Alzheimer's disease (AD) pathology, and whether TDP-43 pathology could help shed light on the phenomenon of resilient cognition in AD. Three-hundred and forty-two subjects pathologically diagnosed with AD were screened for the presence, burden and distribution of TDP-43. All had been classified as cognitively impaired or normal, prior to death. Atlas-based parcellation and voxel-based morphometry were used to assess regional atrophy on MRI. Regression models controlling for age at death, apolipoprotein ε4 and other AD-related pathologies were utilized to explore associations between TDP-43 and cognition or brain atrophy, stratified by Braak stage. In addition, we determined whether the effects of TDP-43 were mediated by hippocampal sclerosis. One-hundred and ninety-five (57%) cases were TDP-positive. After accounting for age, apolipoprotein ε4 and other pathologies, TDP-43 had a strong effect on cognition, memory loss and medial temporal atrophy in AD. These effects were not mediated by hippocampal sclerosis. TDP-positive subjects were 10× more likely to be cognitively impaired at death compared to TDP-negative subjects. Greater cognitive impairment and medial temporal atrophy were associated with greater TDP-43 burden and more extensive TDP-43 distribution. TDP-43 is an important factor in the manifestation of the clinico-imaging features of AD. TDP-43 also appears to be able to overpower what has been termed resilient brain aging. TDP-43 therefore should be considered a potential therapeutic target for the treatment of AD.The aim of this study was to determine whether the TAR DNA-binding protein of 43 kDa (TDP-43) has any independent effect on the clinical and neuroimaging features typically ascribed to Alzheimer's disease (AD) pathology, and whether TDP-43 pathology could help shed light on the phenomenon of resilient cognition in AD. Three-hundred and forty-two subjects pathologically diagnosed with AD were screened for the presence, burden and distribution of TDP-43. All had been classified as cognitively impaired or normal, prior to death. Atlas-based parcellation and voxel-based morphometry were used to assess regional atrophy on MRI. Regression models controlling for age at death, apolipoprotein ε4 and other AD-related pathologies were utilized to explore associations between TDP-43 and cognition or brain atrophy, stratified by Braak stage. In addition, we determined whether the effects of TDP-43 were mediated by hippocampal sclerosis. One-hundred and ninety-five (57%) cases were TDP-positive. After accounting for age, apolipoprotein ε4 and other pathologies, TDP-43 had a strong effect on cognition, memory loss and medial temporal atrophy in AD. These effects were not mediated by hippocampal sclerosis. TDP-positive subjects were 10× more likely to be cognitively impaired at death compared to TDP-negative subjects. Greater cognitive impairment and medial temporal atrophy were associated with greater TDP-43 burden and more extensive TDP-43 distribution. TDP-43 is an important factor in the manifestation of the clinico-imaging features of AD. TDP-43 also appears to be able to overpower what has been termed resilient brain aging. TDP-43 therefore should be considered a potential therapeutic target for the treatment of AD. The aim of this study was to determine whether the TAR DNA-binding protein of 43 kDa (TDP-43) has any independent effect on the clinical and neuroimaging features typically ascribed to Alzheimer's disease (AD) pathology, and whether TDP-43 pathology could help shed light on the phenomenon of resilient cognition in AD. Three-hundred and forty-two subjects pathologically diagnosed with AD were screened for the presence, burden and distribution of TDP-43. All had been classified as cognitively impaired or normal, prior to death. Atlas-based parcellation and voxel-based morphometry were used to assess regional atrophy on MRI. Regression models controlling for age at death, apolipoprotein ε4 and other AD-related pathologies were utilized to explore associations between TDP-43 and cognition or brain atrophy, stratified by Braak stage. In addition, we determined whether the effects of TDP-43 were mediated by hippocampal sclerosis. One-hundred and ninety-five (57%) cases were TDP-positive. After accounting for age, apolipoprotein ε4 and other pathologies, TDP-43 had a strong effect on cognition, memory loss and medial temporal atrophy in AD. These effects were not mediated by hippocampal sclerosis. TDP-positive subjects were 10× more likely to be cognitively impaired at death compared to TDP-negative subjects. Greater cognitive impairment and medial temporal atrophy were associated with greater TDP-43 burden and more extensive TDP-43 distribution. TDP-43 is an important factor in the manifestation of the clinico-imaging features of AD. TDP-43 also appears to be able to overpower what has been termed resilient brain aging. TDP-43 therefore should be considered a potential therapeutic target for the treatment of AD. The aim of this study was to determine whether the TAR DNA-binding protein of 43 kDa (TDP-43) has any independent effect on the clinical and neuroimaging features typically ascribed to Alzheimer's disease (AD) pathology, and whether TDP-43 pathology could help shed light on the phenomenon of resilient cognition in AD. Three-hundred and forty-two subjects pathologically diagnosed with AD were screened for the presence, burden and distribution of TDP-43. All had been classified as cognitively impaired or normal, prior to death. Atlas-based parcellation and voxel-based morphometry were used to assess regional atrophy on MRI. Regression models controlling for age at death, apolipoprotein epsilon 4 and other AD-related pathologies were utilized to explore associations between TDP-43 and cognition or brain atrophy, stratified by Braak stage. In addition, we determined whether the effects of TDP-43 were mediated by hippocampal sclerosis. One-hundred and ninety-five (57 %) cases were TDP-positive. After accounting for age, apolipoprotein epsilon 4 and other pathologies, TDP-43 had a strong effect on cognition, memory loss and medial temporal atrophy in AD. These effects were not mediated by hippocampal sclerosis. TDP-positive subjects were 10 more likely to be cognitively impaired at death compared to TDP-negative subjects. Greater cognitive impairment and medial temporal atrophy were associated with greater TDP-43 burden and more extensive TDP-43 distribution. TDP-43 is an important factor in the manifestation of the clinico-imaging features of AD. TDP-43 also appears to be able to overpower what has been termed resilient brain aging. TDP-43 therefore should be considered a potential therapeutic target for the treatment of AD. |
| Audience | Academic |
| Author | Ivnik, Robert J. Dickson, Dennis W. Jack, Clifford R. Tosakulwong, Nirubol Whitwell, Jennifer L. Weigand, Stephen D. Parisi, Joseph E. Petrucelli, Leonard Petersen, Ronald C. Smith, Glenn E. Boeve, Bradley F. Murray, Melissa E. Knopman, David S. Senjem, Matthew L. Josephs, Keith A. Liesinger, Amanda M. |
| AuthorAffiliation | 3 Department of Health Science Research (Biostatistics), Mayo Clinic, Rochester MN 7 Department of Neuroscience (Neuropathology), Mayo Clinic, Jacksonville, FL 6 Department of Neuropsychiatry (Neuropsychology), Mayo Clinic, Rochester MN 8 Department of Neuroscience (Molecular Neuroscience), Mayo Clinic, Jacksonville, FL 5 Department of Laboratory Medicine and Pathology (Neuropathology), Mayo Clinic, Rochester MN 2 Department of Radiology (Radiology Research), Mayo Clinic, Rochester MN 4 Department of Information Technology, Mayo Clinic, Rochester MN 1 Department of Neurology (Behavioral Neurology), Mayo Clinic, Rochester MN |
| AuthorAffiliation_xml | – name: 6 Department of Neuropsychiatry (Neuropsychology), Mayo Clinic, Rochester MN – name: 2 Department of Radiology (Radiology Research), Mayo Clinic, Rochester MN – name: 1 Department of Neurology (Behavioral Neurology), Mayo Clinic, Rochester MN – name: 7 Department of Neuroscience (Neuropathology), Mayo Clinic, Jacksonville, FL – name: 8 Department of Neuroscience (Molecular Neuroscience), Mayo Clinic, Jacksonville, FL – name: 3 Department of Health Science Research (Biostatistics), Mayo Clinic, Rochester MN – name: 4 Department of Information Technology, Mayo Clinic, Rochester MN – name: 5 Department of Laboratory Medicine and Pathology (Neuropathology), Mayo Clinic, Rochester MN |
| Author_xml | – sequence: 1 givenname: Keith A. surname: Josephs fullname: Josephs, Keith A. email: josephs.keith@mayo.edu organization: Department of Neurology (Behavioral Neurology), Mayo Clinic – sequence: 2 givenname: Jennifer L. surname: Whitwell fullname: Whitwell, Jennifer L. organization: Department of Radiology (Radiology Research), Mayo Clinic – sequence: 3 givenname: Stephen D. surname: Weigand fullname: Weigand, Stephen D. organization: Department of Health Science Research (Biostatistics), Mayo Clinic – sequence: 4 givenname: Melissa E. surname: Murray fullname: Murray, Melissa E. organization: Department of Neuroscience (Neuropathology), Mayo Clinic – sequence: 5 givenname: Nirubol surname: Tosakulwong fullname: Tosakulwong, Nirubol organization: Department of Health Science Research (Biostatistics), Mayo Clinic – sequence: 6 givenname: Amanda M. surname: Liesinger fullname: Liesinger, Amanda M. organization: Department of Neuroscience (Neuropathology), Mayo Clinic – sequence: 7 givenname: Leonard surname: Petrucelli fullname: Petrucelli, Leonard organization: Molecular Neuroscience, Mayo Clinic – sequence: 8 givenname: Matthew L. surname: Senjem fullname: Senjem, Matthew L. organization: Department of Information Technology, Mayo Clinic – sequence: 9 givenname: David S. surname: Knopman fullname: Knopman, David S. organization: Department of Neurology (Behavioral Neurology), Mayo Clinic – sequence: 10 givenname: Bradley F. surname: Boeve fullname: Boeve, Bradley F. organization: Department of Neurology (Behavioral Neurology), Mayo Clinic – sequence: 11 givenname: Robert J. surname: Ivnik fullname: Ivnik, Robert J. organization: Department of Neuropsychiatry (Neuropsychology), Mayo Clinic – sequence: 12 givenname: Glenn E. surname: Smith fullname: Smith, Glenn E. organization: Department of Neuropsychiatry (Neuropsychology), Mayo Clinic – sequence: 13 givenname: Clifford R. surname: Jack fullname: Jack, Clifford R. organization: Department of Radiology (Radiology Research), Mayo Clinic – sequence: 14 givenname: Joseph E. surname: Parisi fullname: Parisi, Joseph E. organization: Department of Laboratory Medicine and Neuropathology, Mayo Clinic – sequence: 15 givenname: Ronald C. surname: Petersen fullname: Petersen, Ronald C. organization: Department of Neurology (Behavioral Neurology), Mayo Clinic – sequence: 16 givenname: Dennis W. surname: Dickson fullname: Dickson, Dennis W. organization: Department of Neuroscience (Neuropathology), Mayo Clinic |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24659241$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFks1uEzEUhS3UiqaFB2CDLLFhM8XXvh7PbJCi8itVgkW7tlzPncRlMhPsSVGy4jV4PZ4ERyn9Ez_ywrL9nWPr-ByyvX7oibFnII5BCPMqCYECCgFYgCzrYvOITQCVLIRWao9NhMinpZLygB2mdJlX0qB-zA4klrqWCBN2fvbmc4GKh8Qd_0JrvuzcmiIPPR_nxH0X-uBdx1ty4ypSplIafHAjNfxbGOd82m3mFBYUf37_kXgTErlET9h-67pET6_nI3b-7u3ZyYfi9NP7jyfT08JrI8aikaYsK1GCqahWraALNLJxpXNY1wZbAk1N4ysQAN4LVSvCCryrNQrU4NQRe73zXa4uFtR46sfoOruMYeHi2g4u2PsnfZjb2XBlEYzUiNng5bVBHL6uKI12EZKnrnM9DatkoYQKEHRV_x_VCiusQVUZffEAvRxWsc9JZEpqqdCU6paauY5s6NshP9FvTe1UmVrm38Ot1_EfqDwaWgSf-9CGvH9P8PxuJjdh_P7zDMAO8HFIKVJ7g4Cw217ZXa9s7pXd9spussY80PgwujEM21hD90-l3ClTvqWfUbyTxV9FvwDDtt8W |
| CitedBy_id | crossref_primary_10_1093_braincomms_fcae183 crossref_primary_10_1002_cne_24397 crossref_primary_10_1016_j_expneurol_2021_113833 crossref_primary_10_3233_JAD_150203 crossref_primary_10_1038_s41598_020_71305_2 crossref_primary_10_1073_pnas_2014349117 crossref_primary_10_1007_s00401_024_02815_w crossref_primary_10_1038_s12276_020_00513_7 crossref_primary_10_1016_j_nbd_2024_106441 crossref_primary_10_1016_j_neurobiolaging_2025_03_001 crossref_primary_10_1016_j_nicl_2022_103125 crossref_primary_10_1007_s00401_023_02653_2 crossref_primary_10_1007_s00401_024_02728_8 crossref_primary_10_4103_1673_5374_386406 crossref_primary_10_1007_s12264_018_0300_0 crossref_primary_10_1093_brain_awz099 crossref_primary_10_1093_cercor_bhaa319 crossref_primary_10_1212_WNL_0000000000003610 crossref_primary_10_1093_brain_awaa299 crossref_primary_10_1016_j_cbi_2022_110065 crossref_primary_10_1002_alz_12291 crossref_primary_10_1074_jbc_TM118_001189 crossref_primary_10_1007_s00415_014_7352_5 crossref_primary_10_1111_neup_12428 crossref_primary_10_3389_bjbs_2024_13169 crossref_primary_10_1038_s41556_022_00988_8 crossref_primary_10_1016_j_neurobiolaging_2015_06_025 crossref_primary_10_1111_bpa_12505 crossref_primary_10_1016_j_jalz_2018_12_016 crossref_primary_10_1186_s40478_015_0215_1 crossref_primary_10_1007_s00018_023_05066_2 crossref_primary_10_3233_JAD_201213 crossref_primary_10_3233_JAD_240136 crossref_primary_10_1111_febs_13651 crossref_primary_10_1021_jacs_0c12729 crossref_primary_10_4103_1673_5374_385301 crossref_primary_10_3233_JAD_220985 crossref_primary_10_1093_brain_awv283 crossref_primary_10_1212_WNL_0000000000200001 crossref_primary_10_1016_j_mcn_2019_103418 crossref_primary_10_3233_ADR_220056 crossref_primary_10_1369_0022155415614303 crossref_primary_10_1073_pnas_2007806117 crossref_primary_10_1186_s40478_024_01916_7 crossref_primary_10_1038_npjamd_2015_3 crossref_primary_10_1080_07391102_2017_1422026 crossref_primary_10_1093_jnen_nlx025 crossref_primary_10_3390_ijms232415670 crossref_primary_10_15252_embj_2021108443 crossref_primary_10_1016_j_jfma_2024_01_018 crossref_primary_10_1016_j_nicl_2020_102369 crossref_primary_10_3233_JAD_181285 crossref_primary_10_1093_brain_awv191 crossref_primary_10_1126_scitranslmed_abe1923 crossref_primary_10_3233_JAD_161116 crossref_primary_10_3233_JAD_220655 crossref_primary_10_1111_nan_12727 crossref_primary_10_15252_embj_2020106177 crossref_primary_10_1111_bpa_13159 crossref_primary_10_1002_hbm_25327 crossref_primary_10_3389_fnagi_2019_00376 crossref_primary_10_3390_ijms25074065 crossref_primary_10_1111_bpa_13277 crossref_primary_10_1021_jacs_2c03845 crossref_primary_10_1093_brain_awaa155 crossref_primary_10_1186_s13024_023_00685_6 crossref_primary_10_1016_j_nbd_2024_106437 crossref_primary_10_1016_j_nicl_2022_102954 crossref_primary_10_1007_s00401_024_02789_9 crossref_primary_10_1016_S1474_4422_18_30251_5 crossref_primary_10_1002_anie_202314587 crossref_primary_10_20900_jpbs_20190017 crossref_primary_10_1093_jnen_nlab122 crossref_primary_10_3389_fnins_2020_00540 crossref_primary_10_1126_scitranslmed_aaz4699 crossref_primary_10_1002_prot_26255 crossref_primary_10_3390_brainsci10080479 crossref_primary_10_1007_s00415_018_9086_2 crossref_primary_10_1212_WNL_0000000000006088 crossref_primary_10_1016_j_bbi_2017_05_014 crossref_primary_10_1007_s00401_022_02524_2 crossref_primary_10_1186_s13024_021_00503_x crossref_primary_10_1021_acs_jpclett_5b00918 crossref_primary_10_3389_fnagi_2022_872629 crossref_primary_10_1093_jnen_nlaa140 crossref_primary_10_1097_NEN_0000000000000151 crossref_primary_10_1111_jnc_15450 crossref_primary_10_1093_brain_aww224 crossref_primary_10_3233_JAD_150494 crossref_primary_10_1007_s00401_016_1637_y crossref_primary_10_1093_brain_awae212 crossref_primary_10_1016_j_neurobiolaging_2019_01_008 crossref_primary_10_1212_WNL_0000000000010454 crossref_primary_10_1186_s40478_022_01386_9 crossref_primary_10_2967_jnumed_113_136069 crossref_primary_10_1007_s00702_014_1304_1 crossref_primary_10_1186_s13195_020_00712_4 crossref_primary_10_1177_17590914231158218 crossref_primary_10_4103_1673_5374_200800 crossref_primary_10_3390_ijms20133230 crossref_primary_10_1016_j_jalz_2018_07_215 crossref_primary_10_1111_nan_12599 crossref_primary_10_1093_jmcb_mjab028 crossref_primary_10_1126_scitranslmed_adp5730 crossref_primary_10_1007_s00401_016_1537_1 crossref_primary_10_1186_s40478_016_0368_6 crossref_primary_10_1007_s00401_019_01979_0 crossref_primary_10_1007_s00401_018_1951_7 crossref_primary_10_1186_s12868_020_00586_0 crossref_primary_10_1212_WNL_0000000000200287 crossref_primary_10_1016_j_clinbiochem_2019_06_004 crossref_primary_10_1097_YCO_0000000000000179 crossref_primary_10_1159_000457127 crossref_primary_10_3390_ijms232415755 crossref_primary_10_1021_acsnano_4c15283 crossref_primary_10_1111_neup_70000 crossref_primary_10_1093_jnen_nlw014 crossref_primary_10_1111_ene_12761 crossref_primary_10_1242_dmm_049323 crossref_primary_10_1371_journal_pone_0180828 crossref_primary_10_1002_alz_12079 crossref_primary_10_1007_s12035_015_9264_5 crossref_primary_10_1097_NEN_0000000000000179 crossref_primary_10_1093_nar_gkx175 crossref_primary_10_1093_jnen_nlaf010 crossref_primary_10_1111_neup_12723 crossref_primary_10_1093_braincomms_fcaa167 crossref_primary_10_1016_j_parkreldis_2024_106041 crossref_primary_10_1371_journal_pbio_1002338 crossref_primary_10_1586_14760584_2016_1121815 crossref_primary_10_1007_s00401_022_02449_w crossref_primary_10_1016_j_neurobiolaging_2019_01_022 crossref_primary_10_3390_ijms17020189 crossref_primary_10_1021_jacs_3c00932 crossref_primary_10_31083_j_fbl2810255 crossref_primary_10_1101_cshperspect_a024554 crossref_primary_10_1186_s40478_021_01260_0 crossref_primary_10_1007_s00401_014_1358_z crossref_primary_10_1080_14728222_2018_1439923 crossref_primary_10_3389_fnmol_2020_00026 crossref_primary_10_1038_s41598_020_63398_6 crossref_primary_10_5858_arpa_2016_0469_SA crossref_primary_10_3233_JAD_161028 crossref_primary_10_1002_alz_12763 crossref_primary_10_1007_s40291_024_00738_6 crossref_primary_10_1016_j_neurobiolaging_2022_05_009 crossref_primary_10_3233_JAD_190368 crossref_primary_10_1016_j_brainresbull_2022_10_006 crossref_primary_10_1074_jbc_RA118_005889 crossref_primary_10_1007_s00401_017_1701_2 crossref_primary_10_1007_s00702_015_1410_8 crossref_primary_10_1002_ana_24388 crossref_primary_10_1016_j_csbj_2023_01_022 crossref_primary_10_1016_j_jns_2024_123319 crossref_primary_10_1038_s41583_023_00731_8 crossref_primary_10_1126_scitranslmed_abo6889 crossref_primary_10_1007_s11357_021_00407_0 crossref_primary_10_1093_jnen_nlae027 crossref_primary_10_1002_ange_202314587 crossref_primary_10_1038_cddis_2015_69 crossref_primary_10_1007_s00401_019_02077_x crossref_primary_10_1038_s41380_021_01346_0 crossref_primary_10_3233_JAD_201166 crossref_primary_10_3389_fnagi_2025_1535280 crossref_primary_10_1038_s41582_022_00642_9 crossref_primary_10_1016_j_neurobiolaging_2018_10_013 crossref_primary_10_1007_s00401_020_02211_0 crossref_primary_10_1016_j_trci_2016_09_002 crossref_primary_10_1111_nan_12309 crossref_primary_10_1093_brain_awy049 crossref_primary_10_1111_bpa_13213 crossref_primary_10_1111_nan_12664 crossref_primary_10_1021_acs_biochem_9b00905 crossref_primary_10_1097_WCO_0000000000000225 crossref_primary_10_3233_JAD_191040 crossref_primary_10_3389_fneur_2020_598907 crossref_primary_10_3390_cells11192997 crossref_primary_10_1002_ana_25246 crossref_primary_10_1098_rsos_210160 crossref_primary_10_1038_srep33996 crossref_primary_10_1186_s13024_019_0333_5 crossref_primary_10_1016_j_bbrc_2020_01_122 crossref_primary_10_1176_appi_ajp_2018_17080858 crossref_primary_10_1016_j_jalz_2016_02_007 crossref_primary_10_1001_jamaneurol_2020_1741 crossref_primary_10_1002_mds_26809 crossref_primary_10_1016_j_nbd_2019_104514 crossref_primary_10_1126_science_abq5622 crossref_primary_10_1186_s12868_017_0334_7 crossref_primary_10_1186_s13195_014_0085_y crossref_primary_10_1007_s00401_016_1600_y crossref_primary_10_1186_s13024_023_00653_0 crossref_primary_10_1007_s00109_023_02407_3 crossref_primary_10_3233_JAD_215567 crossref_primary_10_1111_nan_12430 crossref_primary_10_1186_s13195_014_0082_1 crossref_primary_10_1016_j_mcn_2015_02_016 crossref_primary_10_1016_j_pneurobio_2016_03_003 crossref_primary_10_1126_science_abb4309 crossref_primary_10_5939_sjws_240005 crossref_primary_10_1038_s41593_018_0240_z crossref_primary_10_1111_bpa_13304 crossref_primary_10_1016_j_ajpath_2020_04_009 crossref_primary_10_1016_S1474_4422_17_30284_3 crossref_primary_10_3389_fnagi_2022_858429 crossref_primary_10_3389_fnagi_2017_00311 crossref_primary_10_1016_j_molmed_2022_05_008 crossref_primary_10_1093_brain_awaa315 crossref_primary_10_1093_brain_awz277 crossref_primary_10_1093_jnen_nlad035 crossref_primary_10_1136_jnnp_2015_311321 crossref_primary_10_1016_j_bbrc_2017_02_139 crossref_primary_10_1016_j_biopsych_2020_01_016 crossref_primary_10_1016_j_bbrc_2016_03_158 crossref_primary_10_1093_braincomms_fcae442 crossref_primary_10_1016_j_bbrc_2019_05_006 crossref_primary_10_1016_j_nicl_2021_102816 crossref_primary_10_1038_s41582_019_0228_7 crossref_primary_10_1016_j_neurobiolaging_2025_02_008 crossref_primary_10_1016_j_cger_2022_07_005 crossref_primary_10_3390_ijms251910797 crossref_primary_10_1074_jbc_RA118_007222 crossref_primary_10_1111_neup_12938 crossref_primary_10_1002_dad2_12365 crossref_primary_10_1002_ana_26580 crossref_primary_10_1093_brain_awv220 crossref_primary_10_1016_j_nbd_2017_04_012 crossref_primary_10_1212_WNL_0000000000008679 crossref_primary_10_1212_WNL_0000000000010192 crossref_primary_10_1016_j_neurobiolaging_2022_04_013 crossref_primary_10_1186_s13024_019_0306_8 crossref_primary_10_1016_j_bbrc_2018_03_121 crossref_primary_10_1080_13554794_2018_1494290 crossref_primary_10_14283_jpad_2023_111 crossref_primary_10_1016_j_supmat_2023_100049 crossref_primary_10_1038_s44321_024_00162_7 crossref_primary_10_1007_s00401_020_02207_w crossref_primary_10_1212_WNL_0000000000011397 crossref_primary_10_3233_JAD_221094 crossref_primary_10_1038_mp_2016_38 crossref_primary_10_1007_s00401_017_1681_2 crossref_primary_10_1177_1756286419888819 crossref_primary_10_3389_fncel_2022_954912 crossref_primary_10_1038_nn_4018 crossref_primary_10_1371_journal_pone_0231720 crossref_primary_10_3389_fnins_2018_00259 crossref_primary_10_1007_s40263_019_00613_7 crossref_primary_10_1186_s40478_021_01300_9 crossref_primary_10_3233_JAD_220558 crossref_primary_10_1007_s00401_023_02655_0 crossref_primary_10_1007_s00401_015_1406_3 crossref_primary_10_1186_s40478_020_00961_2 crossref_primary_10_1016_j_clinbiochem_2019_08_005 crossref_primary_10_1016_j_neurobiolaging_2020_04_001 crossref_primary_10_1002_acn3_51038 crossref_primary_10_1038_s41467_024_52299_1 crossref_primary_10_1111_bpa_12424 crossref_primary_10_1186_s40478_019_0743_1 crossref_primary_10_1186_s40478_020_00934_5 crossref_primary_10_3233_JAD_200600 crossref_primary_10_1002_jnr_23725 crossref_primary_10_3934_Neuroscience_2016_4_433 crossref_primary_10_1038_s41598_020_80524_6 crossref_primary_10_1111_febs_17413 crossref_primary_10_1038_s41591_023_02788_5 crossref_primary_10_1080_15548627_2021_2013653 crossref_primary_10_1007_s00415_020_09718_2 crossref_primary_10_1007_s00401_014_1380_1 crossref_primary_10_1007_s00401_020_02222_x crossref_primary_10_1038_s41582_023_00846_7 crossref_primary_10_1097_NEN_0000000000000204 crossref_primary_10_1186_s12868_018_0416_1 crossref_primary_10_1186_s13195_022_00992_y crossref_primary_10_1186_s12883_016_0765_2 crossref_primary_10_4103_1673_5374_268971 crossref_primary_10_1017_S1355617724000146 crossref_primary_10_1186_s13024_025_00819_y crossref_primary_10_1001_jamaneurol_2018_3139 crossref_primary_10_1016_j_jalz_2019_03_003 crossref_primary_10_1111_bpa_12775 crossref_primary_10_1016_j_isci_2024_109522 crossref_primary_10_4103_1673_5374_293142 crossref_primary_10_1097_WAD_0000000000000389 crossref_primary_10_1212_WNL_0000000000010602 crossref_primary_10_1186_s40478_022_01319_6 crossref_primary_10_1007_s00428_022_03462_w crossref_primary_10_1038_s44319_024_00238_y crossref_primary_10_1007_s00401_022_02444_1 crossref_primary_10_1007_s10072_025_08100_2 crossref_primary_10_1007_s00401_023_02671_0 crossref_primary_10_1016_j_nbas_2023_100065 crossref_primary_10_1002_mds_28011 crossref_primary_10_1186_s40478_022_01432_6 crossref_primary_10_3389_fnins_2024_1352822 crossref_primary_10_3389_fnagi_2020_00166 crossref_primary_10_1002_trc2_12305 crossref_primary_10_1212_WNL_0000000000010952 crossref_primary_10_1212_WNL_0000000000009722 crossref_primary_10_1002_ana_24493 crossref_primary_10_1002_glia_24096 crossref_primary_10_1007_s00401_017_1717_7 crossref_primary_10_1042_BSR20200435 crossref_primary_10_1007_s00401_022_02421_8 crossref_primary_10_1038_s41467_023_36023_z crossref_primary_10_1155_2018_8740284 crossref_primary_10_1007_s00401_022_02432_5 crossref_primary_10_1007_s00415_024_12312_5 crossref_primary_10_1093_brain_awab437 crossref_primary_10_1093_brain_aww197 crossref_primary_10_1016_j_jalz_2018_02_020 crossref_primary_10_1016_S1474_4422_18_30288_6 crossref_primary_10_3233_JAD_180169 crossref_primary_10_1038_s41593_023_01341_4 crossref_primary_10_1126_science_adg8501 crossref_primary_10_1186_s40478_023_01656_0 crossref_primary_10_1212_WNL_0000000000001322 crossref_primary_10_1016_j_ejmech_2021_113753 crossref_primary_10_1371_journal_pmed_1002267 crossref_primary_10_3390_ijms252212380 crossref_primary_10_1111_jnc_13588 crossref_primary_10_1126_sciadv_adj4457 |
| Cites_doi | 10.1126/science.8346443 10.1093/ije/dys213 10.1093/brain/awt171 10.1212/WNL.41.4.479 10.1073/pnas.0900688106 10.1016/S1474-4422(12)70200-4 10.1212/WNL.43.11.2412-a 10.1016/j.neurobiolaging.2012.03.004 10.1016/j.neuroimage.2005.02.018 10.1001/archneur.61.10.1579 10.1007/s00401-010-0681-2 10.1016/S1474-4422(11)70156-9 10.1006/nimg.2000.0582 10.1177/1066896906292274 10.1212/WNL.58.5.750 10.1093/brain/awm336 10.1006/nimg.2001.0978 10.1016/S0197-4580(97)00057-2 10.1097/00005072-199904000-00008 10.1007/s00401-008-0400-4 10.1086/420978 10.1016/0165-0270(94)90168-6 10.1212/01.wnl.0000304041.09418.b1 10.1016/j.neurobiolaging.2009.10.012 10.1007/s00401-013-1211-9 10.1016/j.neurobiolaging.2006.10.032 10.1126/science.1134108 10.1097/NEN.0b013e31817713b5 10.1212/WNL.58.10.1476 10.1002/ana.21154 10.1007/BF00293396 10.1007/s00401-011-0879-y 10.1093/brain/awr053 10.1007/BF00308809 10.1007/s00401-012-1044-y 10.1016/0022-3956(75)90026-6 10.1212/01.wnl.0000324924.91351.7d 10.1176/appi.neuropsych.12.2.233 10.1111/j.1365-2990.2005.00635.x 10.1007/s00401-008-0480-1 10.1001/jama.1997.03540340047031 10.1097/WAD.0b013e31820f8f50 10.1126/scitranslmed.3006373 10.3233/JAD-131880 |
| ContentType | Journal Article |
| Copyright | Springer-Verlag Berlin Heidelberg 2014 COPYRIGHT 2014 Springer |
| Copyright_xml | – notice: Springer-Verlag Berlin Heidelberg 2014 – notice: COPYRIGHT 2014 Springer |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TK 7U9 7X7 7XB 88E 88G 8AO 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ H94 K9. M0S M1P M2M PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM |
| DOI | 10.1007/s00401-014-1269-z |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database Psychology Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Psychology MEDLINE - Academic MEDLINE Neurosciences Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1432-0533 |
| EndPage | 824 |
| ExternalDocumentID | PMC4172544 3305880191 A379200048 24659241 10_1007_s00401_014_1269_z |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation_xml | – fundername: NIA NIH HHS grantid: R01-AG037491 – fundername: NIA NIH HHS grantid: P50 AG016574 – fundername: NIA NIH HHS grantid: R21 AG038736 – fundername: NIA NIH HHS grantid: R01 AG037491 – fundername: NIA NIH HHS grantid: R21-AG038736 – fundername: NIA NIH HHS grantid: P50-AG016574 – fundername: NIA NIH HHS grantid: R01 AG011378 – fundername: NIA NIH HHS grantid: R01-AG011378 |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .55 .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 23M 28- 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 78A 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABIVO ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFEXP AFFNX AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN AZQEC B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DWQXO EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO IHE IHR IJ- IKXTQ IMOTQ INH INR IPY ITC ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH L7B LAS LLZTM M1P M2M M4Y MA- N2Q NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PSYQQ PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WJK WK8 X7M YLTOR Z45 Z7U Z7V Z81 Z82 Z83 Z87 Z8O Z8P Z8U Z8V Z8W Z91 ZGI ZOVNA ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM AEIIB PMFND 7TK 7U9 7XB 8FK ABRTQ H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS PUEGO Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c570t-d2766806178e93f0eb472da6aa49974fe15eddc81011cc0393e481ca9540451a3 |
| IEDL.DBID | U2A |
| ISSN | 0001-6322 1432-0533 |
| IngestDate | Thu Aug 21 14:13:13 EDT 2025 Fri Sep 05 07:48:56 EDT 2025 Thu Sep 04 22:14:44 EDT 2025 Sat Aug 23 14:01:44 EDT 2025 Tue Jun 17 21:22:53 EDT 2025 Tue Jun 10 20:47:58 EDT 2025 Thu Apr 03 07:09:11 EDT 2025 Thu Apr 24 23:11:21 EDT 2025 Tue Jul 01 03:38:09 EDT 2025 Fri Feb 21 02:35:56 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | APOE ε4 Braak stage Alzheimer disease MRI TDP-43 Resilience |
| Language | English |
| License | http://www.springer.com/tdm |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c570t-d2766806178e93f0eb472da6aa49974fe15eddc81011cc0393e481ca9540451a3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
| OpenAccessLink | http://doi.org/10.1007/s00401-014-1269-z |
| PMID | 24659241 |
| PQID | 1525234763 |
| PQPubID | 49178 |
| PageCount | 14 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4172544 proquest_miscellaneous_1618141589 proquest_miscellaneous_1534849138 proquest_journals_1525234763 gale_infotracmisc_A379200048 gale_infotracacademiconefile_A379200048 pubmed_primary_24659241 crossref_primary_10_1007_s00401_014_1269_z crossref_citationtrail_10_1007_s00401_014_1269_z springer_journals_10_1007_s00401_014_1269_z |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-06-01 |
| PublicationDateYYYYMMDD | 2014-06-01 |
| PublicationDate_xml | – month: 06 year: 2014 text: 2014-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationSubtitle | Pathology and Mechanisms of Neurological Disease |
| PublicationTitle | Acta neuropathologica |
| PublicationTitleAbbrev | Acta Neuropathol |
| PublicationTitleAlternate | Acta Neuropathol |
| PublicationYear | 2014 |
| Publisher | Springer Berlin Heidelberg Springer Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer – name: Springer Nature B.V |
| References | Sullivan, Greenland (CR40) 2013; 42 Whitwell, Jack, Przybelski (CR45) 2011; 32 Braak, Braak (CR9) 1991; 82 Whitwell, Dickson, Murray (CR46) 2012; 11 Perez-Nievas, Stein, Tai (CR37) 2013; 136 Josephs, Tsuboi, Cookson, Watt, Dickson (CR23) 2004; 61 Agresti, Coull (CR1) 1998; 52 Alzheimer (CR2) 1907; 64 Dickson, Davies, Bevona (CR16) 1994; 88 Janocko, Brodersen, Soto-Ortolaza (CR22) 2012; 124 Brenowitz, Monsell, Schmitt, Kukull, Nelson (CR10) 2014; 39 Hu, Josephs, Knopman (CR19) 2008; 116 Kaufer, Cummings, Ketchel (CR28) 2000; 12 Tzourio-Mazoyer, Landeau, Papathanassiou (CR42) 2002; 15 Amador-Ortiz, Lin, Ahmed (CR3) 2007; 61 Buratti, Brindisi, Pagani, Baralle (CR11) 2004; 74 Josephs, Murray, Whitwell (CR26) 2014; 127 Jack, Lowe, Senjem (CR21) 2008; 131 Mirra, Heyman, McKeel (CR30) 1991; 41 Murray, Graff-Radford, Ross, Petersen, Duara, Dickson (CR32) 2011; 10 Josephs, Whitwell, Parisi (CR25) 2008; 29 Snowdon, Greiner, Mortimer, Riley, Greiner, Markesbery (CR39) 1997; 277 Corder, Saunders, Strittmatter (CR12) 1993; 261 Pavlopoulos, Jones, Kosmidis (CR36) 2013; 5 Neumann, Sampathu, Kwong (CR34) 2006; 314 Davis, Schmitt, Wekstein, Markesbery (CR15) 1999; 58 Whitwell, Josephs, Murray (CR44) 2008; 71 Nelson, Schmitt, Lin (CR33) 2011; 134 CR29 Thal, Schultz, Botez (CR41) 2005; 31 Uryu, Nakashima-Yasuda, Forman (CR43) 2008; 67 Kaplan, Goodglass, Weintraub (CR27) 1983 Ashburner, Friston (CR6) 2000; 11 Jack, Dickson, Parisi (CR20) 2002; 58 Bigio, Mishra, Hatanpaa (CR8) 2010; 120 Davidson, Raby, Foulds (CR14) 2011; 122 Gosche, Mortimer, Smith, Markesbery, Snowdon (CR18) 2002; 58 Morris (CR31) 1993; 43 Josephs, Whitwell, Knopman (CR24) 2008; 70 Zhang, Xu, Cook (CR48) 2009; 106 Arai, Mackenzie, Hasegawa (CR4) 2009; 117 Ashburner, Friston (CR7) 2005; 26 Folstein, Folstein, McHugh (CR17) 1975; 12 Rojo, Garcia, Mateos, Garcia, Vicente (CR38) 2006; 14 Crook, Hardy, Duff (CR13) 1994; 53 (CR47) 1997; 18 Pao, Dickson, Crook, Finch, Rademakers, Graff-Radford (CR35) 2011; 25 Arnold, Louneva, Cao (CR5) 2013; 34 T Arai (1269_CR4) 2009; 117 J Ashburner (1269_CR7) 2005; 26 WC Pao (1269_CR35) 2011; 25 EH Corder (1269_CR12) 1993; 261 DG Davis (1269_CR15) 1999; 58 CR Jack Jr (1269_CR21) 2008; 131 BG Perez-Nievas (1269_CR37) 2013; 136 A Agresti (1269_CR1) 1998; 52 M Neumann (1269_CR34) 2006; 314 J Ashburner (1269_CR6) 2000; 11 DW Dickson (1269_CR16) 1994; 88 SE Arnold (1269_CR5) 2013; 34 WT Hu (1269_CR19) 2008; 116 CR Jack Jr (1269_CR20) 2002; 58 K Uryu (1269_CR43) 2008; 67 EH Bigio (1269_CR8) 2010; 120 C Amador-Ortiz (1269_CR3) 2007; 61 WD Brenowitz (1269_CR10) 2014; 39 DI Kaufer (1269_CR28) 2000; 12 JL Whitwell (1269_CR45) 2011; 32 E Kaplan (1269_CR27) 1983 KM Gosche (1269_CR18) 2002; 58 SS Mirra (1269_CR30) 1991; 41 E Buratti (1269_CR11) 2004; 74 JL Whitwell (1269_CR44) 2008; 71 ME Murray (1269_CR32) 2011; 10 YJ Zhang (1269_CR48) 2009; 106 KA Josephs (1269_CR23) 2004; 61 DA Snowdon (1269_CR39) 1997; 277 JL Whitwell (1269_CR46) 2012; 11 SG Sullivan (1269_CR40) 2013; 42 KA Josephs (1269_CR26) 2014; 127 A Alzheimer (1269_CR2) 1907; 64 KA Josephs (1269_CR24) 2008; 70 H Braak (1269_CR9) 1991; 82 MF Folstein (1269_CR17) 1975; 12 PT Nelson (1269_CR33) 2011; 134 1269_CR29 MG Rojo (1269_CR38) 2006; 14 NJ Janocko (1269_CR22) 2012; 124 N Tzourio-Mazoyer (1269_CR42) 2002; 15 WorkingGroup (1269_CR47) 1997; 18 DR Thal (1269_CR41) 2005; 31 E Pavlopoulos (1269_CR36) 2013; 5 KA Josephs (1269_CR25) 2008; 29 R Crook (1269_CR13) 1994; 53 YS Davidson (1269_CR14) 2011; 122 JC Morris (1269_CR31) 1993; 43 11889239 - Neurology. 2002 Mar 12;58(5):750-7 18592255 - Acta Neuropathol. 2008 Aug;116(2):215-20 7823614 - J Neurosci Methods. 1994 Aug;53(2):125-7 11001602 - J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-9 21596774 - Brain. 2011 May;134(Pt 5):1506-18 21346515 - Alzheimer Dis Assoc Disord. 2011 Oct-Dec;25(4):364-8 17023659 - Science. 2006 Oct 6;314(5796):130-3 17041192 - Int J Surg Pathol. 2006 Oct;14(4):285-305 18520774 - J Neuropathol Exp Neurol. 2008 Jun;67(6):555-64 19383787 - Proc Natl Acad Sci U S A. 2009 May 5;106(18):7607-12 18765650 - Neurology. 2008 Sep 2;71(10):743-9 8346443 - Science. 1993 Aug 13;261(5123):921-3 23986399 - Sci Transl Med. 2013 Aug 28;5(200):200ra115 10218633 - J Neuropathol Exp Neurol. 1999 Apr;58(4):376-88 15955494 - Neuroimage. 2005 Jul 1;26(3):839-51 1202204 - J Psychiatr Res. 1975 Nov;12(3):189-98 18401022 - Neurology. 2008 May 6;70(19 Pt 2):1850-7 10860804 - Neuroimage. 2000 Jun;11(6 Pt 1):805-21 9330978 - Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S1-2 17188783 - Neurobiol Aging. 2008 Apr;29(4):566-73 21802369 - Lancet Neurol. 2011 Sep;10(9):785-96 23230299 - Int J Epidemiol. 2013 Feb;42(1):308-17 8232972 - Neurology. 1993 Nov;43(11):2412-4 15885064 - Neuropathol Appl Neurobiol. 2005 Jun;31(3):270-9 1759558 - Acta Neuropathol. 1991;82(4):239-59 19139911 - Acta Neuropathol. 2009 Feb;117(2):125-36 23824488 - Brain. 2013 Aug;136(Pt 8):2510-26 15477512 - Arch Neurol. 2004 Oct;61(10):1579-84 20361198 - Acta Neuropathol. 2010 Jul;120(1):43-54 12034782 - Neurology. 2002 May 28;58(10):1476-82 21968532 - Acta Neuropathol. 2011 Dec;122(6):703-13 18263627 - Brain. 2008 Mar;131(Pt 3):665-80 22554416 - Neurobiol Aging. 2013 Jan;34(1):157-68 19914744 - Neurobiol Aging. 2011 Sep;32(9):1531-41 2011243 - Neurology. 1991 Apr;41(4):479-86 17469117 - Ann Neurol. 2007 May;61(5):435-45 22951070 - Lancet Neurol. 2012 Oct;11(10):868-77 7810292 - Acta Neuropathol. 1994;88(3):212-21 22968369 - Acta Neuropathol. 2012 Nov;124(5):681-92 24240737 - Acta Neuropathol. 2014 Mar;127(3):441-50 15195661 - Am J Hum Genet. 2004 Jun;74(6):1322-5 11771995 - Neuroimage. 2002 Jan;15(1):273-89 9052711 - JAMA. 1997 Mar 12;277(10):813-7 24270205 - J Alzheimers Dis. 2014;39(3):691-702 |
| References_xml | – volume: 261 start-page: 921 year: 1993 end-page: 923 ident: CR12 article-title: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families publication-title: Science doi: 10.1126/science.8346443 – volume: 42 start-page: 308 year: 2013 end-page: 317 ident: CR40 article-title: Bayesian regression in SAS software publication-title: Int J Epidemiol doi: 10.1093/ije/dys213 – volume: 136 start-page: 2510 year: 2013 end-page: 2526 ident: CR37 article-title: Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology publication-title: Brain J Neurol doi: 10.1093/brain/awt171 – volume: 64 start-page: 146 year: 1907 end-page: 148 ident: CR2 article-title: Über eine eigenartige Erkrankung der Hirnrinde publication-title: Allgemeine Zeitschrift für Psychiatrie und Psychisch-Gerichtliche Medizin – year: 1983 ident: CR27 publication-title: The Boston Naming Test – volume: 41 start-page: 479 year: 1991 end-page: 486 ident: CR30 article-title: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease publication-title: Neurology doi: 10.1212/WNL.41.4.479 – volume: 106 start-page: 7607 year: 2009 end-page: 7612 ident: CR48 article-title: Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0900688106 – volume: 11 start-page: 868 year: 2012 end-page: 877 ident: CR46 article-title: Neuroimaging correlates of pathologically defined subtypes of Alzheimer’s disease: a case-control study publication-title: Lancet Neurol doi: 10.1016/S1474-4422(12)70200-4 – volume: 43 start-page: 2412 year: 1993 end-page: 2414 ident: CR31 article-title: The Clinical Dementia Rating (CDR): current version and scoring rules publication-title: Neurology doi: 10.1212/WNL.43.11.2412-a – volume: 34 start-page: 157 year: 2013 end-page: 168 ident: CR5 article-title: Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer’s disease publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2012.03.004 – volume: 26 start-page: 839 year: 2005 end-page: 851 ident: CR7 article-title: Unified segmentation publication-title: NeuroImage doi: 10.1016/j.neuroimage.2005.02.018 – volume: 61 start-page: 1579 year: 2004 end-page: 1584 ident: CR23 article-title: Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration publication-title: Arch Neurol doi: 10.1001/archneur.61.10.1579 – volume: 120 start-page: 43 year: 2010 end-page: 54 ident: CR8 article-title: TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease publication-title: Acta Neuropathol doi: 10.1007/s00401-010-0681-2 – volume: 10 start-page: 785 year: 2011 end-page: 796 ident: CR32 article-title: Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study publication-title: Lancet Neurol doi: 10.1016/S1474-4422(11)70156-9 – volume: 11 start-page: 805 year: 2000 end-page: 821 ident: CR6 article-title: Voxel-based morphometry—the methods publication-title: NeuroImage doi: 10.1006/nimg.2000.0582 – volume: 39 start-page: 691 year: 2014 end-page: 702 ident: CR10 article-title: Hippocampal sclerosis of aging is a key Alzheimer’s Disease mimic: clinical-pathologic correlations and comparisons with both Alzheimer’s Disease and non-tauopathic frontotemporal lobar degeneration publication-title: J Alzheimers Dis – volume: 14 start-page: 285 year: 2006 end-page: 305 ident: CR38 article-title: Critical comparison of 31 commercially available digital slide systems in pathology publication-title: Int J Surg Pathol doi: 10.1177/1066896906292274 – volume: 58 start-page: 750 year: 2002 end-page: 757 ident: CR20 article-title: Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia publication-title: Neurology doi: 10.1212/WNL.58.5.750 – volume: 131 start-page: 665 year: 2008 end-page: 680 ident: CR21 article-title: 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment publication-title: Brain J Neurol doi: 10.1093/brain/awm336 – volume: 15 start-page: 273 year: 2002 end-page: 289 ident: CR42 article-title: Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain publication-title: NeuroImage doi: 10.1006/nimg.2001.0978 – volume: 18 start-page: S1 year: 1997 end-page: S2 ident: CR47 article-title: Consensus recommendation for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for Neuropathologic Assessment of Alzheimer’s Disease publication-title: Neurobiol Aging doi: 10.1016/S0197-4580(97)00057-2 – volume: 58 start-page: 376 year: 1999 end-page: 388 ident: CR15 article-title: Alzheimer neuropathologic alterations in aged cognitively normal subjects publication-title: J Neuropathol Exp Neurol doi: 10.1097/00005072-199904000-00008 – volume: 116 start-page: 215 year: 2008 end-page: 220 ident: CR19 article-title: Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease publication-title: Acta Neuropathol doi: 10.1007/s00401-008-0400-4 – ident: CR29 – volume: 74 start-page: 1322 year: 2004 end-page: 1325 ident: CR11 article-title: Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: a functional link with disease penetrance publication-title: Am J Hum Genet doi: 10.1086/420978 – volume: 53 start-page: 125 year: 1994 end-page: 127 ident: CR13 article-title: Single-day apolipoprotein E genotyping publication-title: J Neurosci Methods doi: 10.1016/0165-0270(94)90168-6 – volume: 70 start-page: 1850 year: 2008 end-page: 1857 ident: CR24 article-title: Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype publication-title: Neurology doi: 10.1212/01.wnl.0000304041.09418.b1 – volume: 32 start-page: 1531 year: 2011 end-page: 1541 ident: CR45 article-title: Temporoparietal atrophy: A marker of AD pathology independent of clinical diagnosis publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2009.10.012 – volume: 127 start-page: 441 year: 2014 end-page: 450 ident: CR26 article-title: Staging TDP-43 pathology in Alzheimer’s disease publication-title: Acta Neuropathol doi: 10.1007/s00401-013-1211-9 – volume: 29 start-page: 566 year: 2008 end-page: 573 ident: CR25 article-title: Argyrophilic grains: a distinct disease or an additive pathology? publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2006.10.032 – volume: 314 start-page: 130 year: 2006 end-page: 133 ident: CR34 article-title: Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis publication-title: Science doi: 10.1126/science.1134108 – volume: 67 start-page: 555 year: 2008 end-page: 564 ident: CR43 article-title: Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies publication-title: J Neuropathol Exp Neurol doi: 10.1097/NEN.0b013e31817713b5 – volume: 58 start-page: 1476 year: 2002 end-page: 1482 ident: CR18 article-title: Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study publication-title: Neurology doi: 10.1212/WNL.58.10.1476 – volume: 61 start-page: 435 year: 2007 end-page: 445 ident: CR3 article-title: TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease publication-title: Ann Neurol doi: 10.1002/ana.21154 – volume: 88 start-page: 212 year: 1994 end-page: 221 ident: CR16 article-title: Hippocampal sclerosis: a common pathological feature of dementia in very old (≥80 years of age) humans publication-title: Acta Neuropathol doi: 10.1007/BF00293396 – volume: 122 start-page: 703 year: 2011 end-page: 713 ident: CR14 article-title: TDP-43 pathological changes in early onset familial and sporadic Alzheimer’s disease, late onset Alzheimer’s disease and Down’s syndrome: association with age, hippocampal sclerosis and clinical phenotype publication-title: Acta Neuropathol doi: 10.1007/s00401-011-0879-y – volume: 134 start-page: 1506 year: 2011 end-page: 1518 ident: CR33 article-title: Hippocampal sclerosis in advanced age: clinical and pathological features publication-title: Brain J Neurol doi: 10.1093/brain/awr053 – volume: 82 start-page: 239 year: 1991 end-page: 259 ident: CR9 article-title: Neuropathological stageing of Alzheimer-related changes publication-title: Acta Neuropathol doi: 10.1007/BF00308809 – volume: 124 start-page: 681 year: 2012 end-page: 692 ident: CR22 article-title: Neuropathologically defined subtypes of Alzheimer’s disease differ significantly from neurofibrillary tangle-predominant dementia publication-title: Acta Neuropathol doi: 10.1007/s00401-012-1044-y – volume: 12 start-page: 189 year: 1975 end-page: 198 ident: CR17 article-title: “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician publication-title: J Psychiatr Res doi: 10.1016/0022-3956(75)90026-6 – volume: 71 start-page: 743 year: 2008 end-page: 749 ident: CR44 article-title: MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study publication-title: Neurology doi: 10.1212/01.wnl.0000324924.91351.7d – volume: 12 start-page: 233 year: 2000 end-page: 239 ident: CR28 article-title: Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory publication-title: J Neuropsychiatry Clin Neurosci doi: 10.1176/appi.neuropsych.12.2.233 – volume: 5 start-page: 200ra115 year: 2013 ident: CR36 article-title: Molecular mechanism for age-related memory loss: the histone-binding protein RbAp48 publication-title: Sci Transl Med – volume: 52 start-page: 119 year: 1998 end-page: 126 ident: CR1 article-title: Approximate is better than "exact" for interval estimation of binomial proportions publication-title: Am Stat – volume: 31 start-page: 270 year: 2005 end-page: 279 ident: CR41 article-title: The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer’s disease-related pathology publication-title: Neuropathol Appl Neurobiol doi: 10.1111/j.1365-2990.2005.00635.x – volume: 117 start-page: 125 year: 2009 end-page: 136 ident: CR4 article-title: Phosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies publication-title: Acta Neuropathol doi: 10.1007/s00401-008-0480-1 – volume: 277 start-page: 813 year: 1997 end-page: 817 ident: CR39 article-title: Brain infarction and the clinical expression of Alzheimer disease. The Nun Study publication-title: JAMA doi: 10.1001/jama.1997.03540340047031 – volume: 25 start-page: 364 year: 2011 end-page: 368 ident: CR35 article-title: Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking Alzheimer disease clinically publication-title: Alzheimer Dis Assoc Disord doi: 10.1097/WAD.0b013e31820f8f50 – volume: 116 start-page: 215 year: 2008 ident: 1269_CR19 publication-title: Acta Neuropathol doi: 10.1007/s00401-008-0400-4 – volume: 136 start-page: 2510 year: 2013 ident: 1269_CR37 publication-title: Brain J Neurol doi: 10.1093/brain/awt171 – volume: 34 start-page: 157 year: 2013 ident: 1269_CR5 publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2012.03.004 – volume: 43 start-page: 2412 year: 1993 ident: 1269_CR31 publication-title: Neurology doi: 10.1212/WNL.43.11.2412-a – volume: 53 start-page: 125 year: 1994 ident: 1269_CR13 publication-title: J Neurosci Methods doi: 10.1016/0165-0270(94)90168-6 – volume: 12 start-page: 233 year: 2000 ident: 1269_CR28 publication-title: J Neuropsychiatry Clin Neurosci doi: 10.1176/appi.neuropsych.12.2.233 – volume: 10 start-page: 785 year: 2011 ident: 1269_CR32 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(11)70156-9 – volume: 52 start-page: 119 year: 1998 ident: 1269_CR1 publication-title: Am Stat – volume: 58 start-page: 376 year: 1999 ident: 1269_CR15 publication-title: J Neuropathol Exp Neurol doi: 10.1097/00005072-199904000-00008 – volume: 122 start-page: 703 year: 2011 ident: 1269_CR14 publication-title: Acta Neuropathol doi: 10.1007/s00401-011-0879-y – volume-title: The Boston Naming Test year: 1983 ident: 1269_CR27 – volume: 261 start-page: 921 year: 1993 ident: 1269_CR12 publication-title: Science doi: 10.1126/science.8346443 – volume: 29 start-page: 566 year: 2008 ident: 1269_CR25 publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2006.10.032 – volume: 11 start-page: 868 year: 2012 ident: 1269_CR46 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(12)70200-4 – volume: 41 start-page: 479 year: 1991 ident: 1269_CR30 publication-title: Neurology doi: 10.1212/WNL.41.4.479 – volume: 5 start-page: 200ra115 year: 2013 ident: 1269_CR36 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3006373 – volume: 82 start-page: 239 year: 1991 ident: 1269_CR9 publication-title: Acta Neuropathol doi: 10.1007/BF00308809 – volume: 64 start-page: 146 year: 1907 ident: 1269_CR2 publication-title: Allgemeine Zeitschrift für Psychiatrie und Psychisch-Gerichtliche Medizin – volume: 88 start-page: 212 year: 1994 ident: 1269_CR16 publication-title: Acta Neuropathol doi: 10.1007/BF00293396 – volume: 14 start-page: 285 year: 2006 ident: 1269_CR38 publication-title: Int J Surg Pathol doi: 10.1177/1066896906292274 – volume: 124 start-page: 681 year: 2012 ident: 1269_CR22 publication-title: Acta Neuropathol doi: 10.1007/s00401-012-1044-y – volume: 18 start-page: S1 year: 1997 ident: 1269_CR47 publication-title: Neurobiol Aging doi: 10.1016/S0197-4580(97)00057-2 – volume: 31 start-page: 270 year: 2005 ident: 1269_CR41 publication-title: Neuropathol Appl Neurobiol doi: 10.1111/j.1365-2990.2005.00635.x – volume: 39 start-page: 691 year: 2014 ident: 1269_CR10 publication-title: J Alzheimers Dis doi: 10.3233/JAD-131880 – volume: 58 start-page: 750 year: 2002 ident: 1269_CR20 publication-title: Neurology doi: 10.1212/WNL.58.5.750 – ident: 1269_CR29 – volume: 71 start-page: 743 year: 2008 ident: 1269_CR44 publication-title: Neurology doi: 10.1212/01.wnl.0000324924.91351.7d – volume: 127 start-page: 441 year: 2014 ident: 1269_CR26 publication-title: Acta Neuropathol doi: 10.1007/s00401-013-1211-9 – volume: 58 start-page: 1476 year: 2002 ident: 1269_CR18 publication-title: Neurology doi: 10.1212/WNL.58.10.1476 – volume: 70 start-page: 1850 year: 2008 ident: 1269_CR24 publication-title: Neurology doi: 10.1212/01.wnl.0000304041.09418.b1 – volume: 120 start-page: 43 year: 2010 ident: 1269_CR8 publication-title: Acta Neuropathol doi: 10.1007/s00401-010-0681-2 – volume: 61 start-page: 435 year: 2007 ident: 1269_CR3 publication-title: Ann Neurol doi: 10.1002/ana.21154 – volume: 131 start-page: 665 year: 2008 ident: 1269_CR21 publication-title: Brain J Neurol doi: 10.1093/brain/awm336 – volume: 277 start-page: 813 year: 1997 ident: 1269_CR39 publication-title: JAMA doi: 10.1001/jama.1997.03540340047031 – volume: 12 start-page: 189 year: 1975 ident: 1269_CR17 publication-title: J Psychiatr Res doi: 10.1016/0022-3956(75)90026-6 – volume: 15 start-page: 273 year: 2002 ident: 1269_CR42 publication-title: NeuroImage doi: 10.1006/nimg.2001.0978 – volume: 117 start-page: 125 year: 2009 ident: 1269_CR4 publication-title: Acta Neuropathol doi: 10.1007/s00401-008-0480-1 – volume: 11 start-page: 805 year: 2000 ident: 1269_CR6 publication-title: NeuroImage doi: 10.1006/nimg.2000.0582 – volume: 25 start-page: 364 year: 2011 ident: 1269_CR35 publication-title: Alzheimer Dis Assoc Disord doi: 10.1097/WAD.0b013e31820f8f50 – volume: 42 start-page: 308 year: 2013 ident: 1269_CR40 publication-title: Int J Epidemiol doi: 10.1093/ije/dys213 – volume: 134 start-page: 1506 year: 2011 ident: 1269_CR33 publication-title: Brain J Neurol doi: 10.1093/brain/awr053 – volume: 61 start-page: 1579 year: 2004 ident: 1269_CR23 publication-title: Arch Neurol doi: 10.1001/archneur.61.10.1579 – volume: 26 start-page: 839 year: 2005 ident: 1269_CR7 publication-title: NeuroImage doi: 10.1016/j.neuroimage.2005.02.018 – volume: 74 start-page: 1322 year: 2004 ident: 1269_CR11 publication-title: Am J Hum Genet doi: 10.1086/420978 – volume: 67 start-page: 555 year: 2008 ident: 1269_CR43 publication-title: J Neuropathol Exp Neurol doi: 10.1097/NEN.0b013e31817713b5 – volume: 106 start-page: 7607 year: 2009 ident: 1269_CR48 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0900688106 – volume: 314 start-page: 130 year: 2006 ident: 1269_CR34 publication-title: Science doi: 10.1126/science.1134108 – volume: 32 start-page: 1531 year: 2011 ident: 1269_CR45 publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2009.10.012 – reference: 23986399 - Sci Transl Med. 2013 Aug 28;5(200):200ra115 – reference: 11771995 - Neuroimage. 2002 Jan;15(1):273-89 – reference: 1759558 - Acta Neuropathol. 1991;82(4):239-59 – reference: 21596774 - Brain. 2011 May;134(Pt 5):1506-18 – reference: 8232972 - Neurology. 1993 Nov;43(11):2412-4 – reference: 18765650 - Neurology. 2008 Sep 2;71(10):743-9 – reference: 19383787 - Proc Natl Acad Sci U S A. 2009 May 5;106(18):7607-12 – reference: 23230299 - Int J Epidemiol. 2013 Feb;42(1):308-17 – reference: 17188783 - Neurobiol Aging. 2008 Apr;29(4):566-73 – reference: 10218633 - J Neuropathol Exp Neurol. 1999 Apr;58(4):376-88 – reference: 11001602 - J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-9 – reference: 15885064 - Neuropathol Appl Neurobiol. 2005 Jun;31(3):270-9 – reference: 11889239 - Neurology. 2002 Mar 12;58(5):750-7 – reference: 18263627 - Brain. 2008 Mar;131(Pt 3):665-80 – reference: 18592255 - Acta Neuropathol. 2008 Aug;116(2):215-20 – reference: 21346515 - Alzheimer Dis Assoc Disord. 2011 Oct-Dec;25(4):364-8 – reference: 17023659 - Science. 2006 Oct 6;314(5796):130-3 – reference: 15195661 - Am J Hum Genet. 2004 Jun;74(6):1322-5 – reference: 10860804 - Neuroimage. 2000 Jun;11(6 Pt 1):805-21 – reference: 21968532 - Acta Neuropathol. 2011 Dec;122(6):703-13 – reference: 7823614 - J Neurosci Methods. 1994 Aug;53(2):125-7 – reference: 20361198 - Acta Neuropathol. 2010 Jul;120(1):43-54 – reference: 9330978 - Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S1-2 – reference: 18520774 - J Neuropathol Exp Neurol. 2008 Jun;67(6):555-64 – reference: 24270205 - J Alzheimers Dis. 2014;39(3):691-702 – reference: 1202204 - J Psychiatr Res. 1975 Nov;12(3):189-98 – reference: 18401022 - Neurology. 2008 May 6;70(19 Pt 2):1850-7 – reference: 15955494 - Neuroimage. 2005 Jul 1;26(3):839-51 – reference: 19139911 - Acta Neuropathol. 2009 Feb;117(2):125-36 – reference: 22951070 - Lancet Neurol. 2012 Oct;11(10):868-77 – reference: 19914744 - Neurobiol Aging. 2011 Sep;32(9):1531-41 – reference: 22554416 - Neurobiol Aging. 2013 Jan;34(1):157-68 – reference: 8346443 - Science. 1993 Aug 13;261(5123):921-3 – reference: 7810292 - Acta Neuropathol. 1994;88(3):212-21 – reference: 24240737 - Acta Neuropathol. 2014 Mar;127(3):441-50 – reference: 22968369 - Acta Neuropathol. 2012 Nov;124(5):681-92 – reference: 12034782 - Neurology. 2002 May 28;58(10):1476-82 – reference: 2011243 - Neurology. 1991 Apr;41(4):479-86 – reference: 17041192 - Int J Surg Pathol. 2006 Oct;14(4):285-305 – reference: 9052711 - JAMA. 1997 Mar 12;277(10):813-7 – reference: 21802369 - Lancet Neurol. 2011 Sep;10(9):785-96 – reference: 17469117 - Ann Neurol. 2007 May;61(5):435-45 – reference: 15477512 - Arch Neurol. 2004 Oct;61(10):1579-84 – reference: 23824488 - Brain. 2013 Aug;136(Pt 8):2510-26 |
| SSID | ssj0012745 |
| Score | 2.5789137 |
| Snippet | The aim of this study was to determine whether the TAR DNA-binding protein of 43 kDa (TDP-43) has any independent effect on the clinical and neuroimaging... The aim of this study was to determine whether the TAR DNA-binding protein of 43 kDa (TDP-43) has any independent effect on the clinical and neuroimaging... The aim of this study was to determine whether the Tar DNA-binding protein of 43 kDa (TDP-43) has any independent effect on the clinical and neuroimaging... The aim of this study was to determine whether the TAR DNA-binding protein of 43kDa (TDP-43) independently has any effect on the clinical and neuroimaging... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 811 |
| SubjectTerms | Aged Aged, 80 and over Alzheimer Disease - genetics Alzheimer Disease - pathology Alzheimer Disease - physiopathology Alzheimer Disease - psychology Alzheimer's disease Apolipoprotein E4 - genetics Apolipoproteins Atrophy Brain - pathology Brain - physiopathology Brain research Cognition & reasoning Cognition - physiology Cognitive ability Dementia Diagnostic imaging DNA DNA-Binding Proteins - metabolism Female Health aspects Humans Immunohistochemistry Magnetic Resonance Imaging Male Medicine Medicine & Public Health Memory Memory Disorders - genetics Memory Disorders - pathology Memory Disorders - physiopathology Middle Aged Neuropathology Neuropsychology Neurosciences Original Paper Pathology Protein binding Proteins Regression Analysis Sclerosis - pathology Severity of Illness Index |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fa9swEBZbCmMvY7_nrhsaDAobZrZ1kuWnkW0tZdBSthb6ZmRJpoHMyZr0JX9972zZqwPLm0EnI53upE866TvGPoIRFS5EJi7AmxiUxK88r2NZJcqp1Km8Tdp3eqZOLuHnlbwKB26rcK2ynxPbidotLJ2Rf6E8PZkAdIevy78xZY2i6GpIofGQ7eEUrOWE7X07Ojv_NcQRcM_V5TDATbNC2-3jmklHI9pupYm3TxXxZrQybc_P9xao7cuTWxHUdmE6fsqeBETJp50JPGMPfPOcPToNMfMX7PfFj_MYBJ-tuOHosnw5N4iz-azhCP54_zSS177l-ESpMGLecTql5dP55trP_vibwxUP8ZyX7PL46OL7SRxSKcRW5sk6dlmulCa4on0h6sRXkGfOKGNwx5ND7VPpnbPE9pVaS-91PejUmgIBHcjUiFds0iwa_4Zxi5DLF1VqQCiotDUuNdJnwmV1IrUrIpb0aixt4BmndBfzcmBIbjVfouZL0ny5idinocqyI9nYJXxIY1OSA-J_rQnvCLB1RGVVTkVeZO1b-YgdjCTRcey4uB_dMjjuqvxnZhH7MBRTTbqM1vjFLckI0FCkQu-QUQidEBxp1MfrzmCGrmVAsWxII5aPTGkQIMrvcUkzu26pvwHxpgSI2Ofe6O41_X8a29_d0bfscUZe0B4tHbDJ-ubWv0Okta7eB3e6A4xnIk8 priority: 102 providerName: ProQuest |
| Title | TDP-43 is a key player in the clinical features associated with Alzheimer’s disease |
| URI | https://link.springer.com/article/10.1007/s00401-014-1269-z https://www.ncbi.nlm.nih.gov/pubmed/24659241 https://www.proquest.com/docview/1525234763 https://www.proquest.com/docview/1534849138 https://www.proquest.com/docview/1618141589 https://pubmed.ncbi.nlm.nih.gov/PMC4172544 |
| Volume | 127 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NatwwEB6aBEovJf13ky4qFAotBtv6s49uu2loSQglC9uTkSWZLGydkN1c9pTXyOvlSTLjtU28tIGebNDY2KMZ6ZNG8w3AB2F4iRORCTPhTSiUxDutq1CWkXIqdko3RfuOjtXhRPyYymmbx73oTrt3IclmpO6T3cjeaOlLPHsqC1dbsCNx6U7n-CZJ3ocOcJm1LluAwgrNtQtl_u0Vg8loc0i-NydtnpfcCJo2c9HBLjxtQSTL173-DB75-jk8PmrD5C9gcvrtJBSczRbMMPRSdjE3CK3ZrGaI91iXDckq39B6olTbSd4x2phl-Xx15md__OXt9c2CtUGclzA5GJ9-PQzb-gmhlTpahi7RSqWEUVKf8SrypdCJM8oYXOZoUflYeucsUXzF1lKSrhdpbE2GKE7I2PBXsF2f1_4NMIs4y2dlbARXokytcbGRPuEuqSKZuiyAqFNkYVtycapxMS96WuRG9wXqviDdF6sAPvWPXKyZNR4S_ki9U5DX4XutaZMH8OuIv6rIuc6SJkE-gP2BJHqLHTZ3_Vu03rooqAZUwgUOtQG875vpSTqBVvvzK5LhIhVZzNMHZBTiJUREKerj9dpk-l9LBAWwRRyAHhhTL0A838OWenbW8H0LBJlSiAA-d2Z379P_pbG3_yW9B08Scotme2kftpeXV_4doq1lOYItPdUj2Mm___45xuuX8fHJr1Hjc3fDjyPX |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTYK9IL4JDDASaBIoIh-OkzwgVNimjq3VBJ20N-PYjlapS8vaCdE_ir-Ru3yxVKJve4vkc5Sc73w_--zfAbzhKswwECk35Va5XET4FMe5G2WeMMI3Ii6L9g2Gon_Kv55FZxvwp7kLQ8cqmzmxnKjNVNMe-Qeq0xOEHN3h0-ynS1WjKLvalNCozOLI_v6FS7b5x8M9HN-3QXCwP_rSd-uqAq6OYm_hmiAWIqHIndg0zD2b8TgwSiiF4D_mufUja4wm4itfa7q6annia5UituGRr0J87y3YQpiRohdtfd4fnnxr8xa4xqtqJuAiXaCvNHlUr6ItLZfuxBMoUnfZiYSr8eBaQFw9rLmSsS0D4cE9uFsjWNarTO4-bNjiAdwe1Dn6h_B9tHfi8pCN50wxnCLYbKIQ17NxwRBssuYqJsttySmKUrWFWMNoV5j1JstzO76wl7tzVuePHsHpjSj5MWwW08I-BaYR4tk08xUPBc8SrYyvIhuEJsi9KDGpA16jRqlrXnMqrzGRLSNzqXmJmpekebl04F3bZVaReqwT3qWxkeTw-F6t6nsL-HVEnSV7YZwG5d18B3Y6kuioutvcjK6sJ4q5_GfWDrxum6knHX4r7PSKZEKe8NQPkzUyAqEagrEE9fGkMpj21wJOuXPuOxB3TKkVIIrxbksxPi-pxjni24hzB943Rnft0_-nsWfrf_QV3OmPBsfy-HB49By2A_KIcltrBzYXl1f2BaK8Rfaydi0GP27am_8Cv9dd4g |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTpp4QXwTGGAk0CRQtMRxnOQBoUJXbYxVFWzS3oJjO1qlkpa1E6J_Gn8dd_liqUTf9hbJ5yg53_nufL7fAbwWKsjQECk3EVa5Qob4FEW5G2aeNNI3Miqb9p2M5OGZ-Hwenm_Bn6YWhq5VNntiuVGbmaYz8n3q08MDgeqwn9fXIsaD4Yf5T5c6SFGmtWmnUYnIsf39C8O3xfujAa71G86HB6efDt26w4Crw8hbuoZHUsZkxWObBLlnMxFxo6RSGAhEIrd-aI3RBILla01lrFbEvlYJ-jki9FWA770F2xFaxbgH2x8PRuOvbQ4D472qfwIG7BL1psmpehWEaRnGE2agTNxVxyqu24ZrxnH94uZa9rY0isO7cKf2Zlm_Er97sGWL-7BzUufrH8C308HYFQGbLJhiuF2w-VShj88mBUPHkzVlmSy3Jb4oUtXSYg2jE2LWn64u7OSHvdxbsDqX9BDOboTJj6BXzAr7BJhGd88mma9EIEUWa2V8FVoeGJ57YWwSB7yGjamuMc6p1cY0bdGZS86nyPmUOJ-uHHjbTplXAB-biPdobVJSfnyvVnUNA34dwWil_SBKeFmn78BuhxKVVneHm9VN601jkf4TcQdetcM0ky7CFXZ2RTSBiEXiB_EGGoluGzpmMfLjcSUw7a9xQXl04TsQdUSpJSC48e5IMbkoYccF-rqhEA68a4Tu2qf_j2NPN__oS9hBLU6_HI2On8FtTgpRnnDtQm95eWWfo8O3zF7UmsXg-00r819KAmIO |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=TDP-43+is+a+key+player+in+the+clinical+features+associated+with+Alzheimer%27s+disease&rft.jtitle=Acta+neuropathologica&rft.au=Josephs%2C+Keith+A&rft.au=Whitwell%2C+Jennifer+L&rft.au=Weigand%2C+Stephen+D&rft.au=Murray%2C+Melissa+E&rft.date=2014-06-01&rft.pub=Springer&rft.issn=0001-6322&rft.volume=127&rft.issue=6&rft.spage=811&rft_id=info:doi/10.1007%2Fs00401-014-1269-z&rft.externalDocID=A379200048 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0001-6322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0001-6322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0001-6322&client=summon |